您好,欢迎您

【2021 ASCO-GI】12项研究入选口头报告,具体研究先睹为快!

2020年12月24日
整理:肿瘤资讯
来源:肿瘤资讯

当地时间1月15~17日,2021年首场肿瘤学学术盛会——美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO-GI)将以线上会议的形式举办,一如既往带来消化道肿瘤领域的最新进展。今年入选口头报告(Oral abstract)的12项研究中,包括食管/胃癌相关研究、肛门和结肠直肠癌相关研究以及肝胆癌、神经内分泌肿瘤/类癌、胰腺癌和小肠癌相关研究各4篇。具体是哪些研究呢?我们先睹为快!

微信图片_20201222163318.jpg

食管癌/胃癌

Friday, January 15,11:00 PM - 12:15 AM CST

JACCRO GC-07研究:病理分期Ⅲ期胃癌根治性切除术后辅助S-1 vs S-1 +多西他赛治疗的3年RFS和OS(Abs 159)

Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07).

随机双盲安慰剂对照Ⅱ期FIGHT 研究:Bemarituzumab联合mFOLFOX6一线治疗进展期胃/胃食管交界部腺癌(Abs 160)

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

DELIVER研究(JACCRO GC-08):肠道菌群基因组通路预测纳武利尤单抗在进展期胃癌中的疗效(Abs 161)

Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).

局部进展期胸段食管癌术前治疗对围手术期并发症风险的影响:多中心Ⅲ期JCOG 1109研究结果(Abs 162)

Impact of preoperative therapy for locally advanced thoracic esophageal cancer on the risk of perioperative complications: Results from multicenter phase III trial JCOG 1109.

肛门癌和结直肠癌

Saturday, January 16,10:00 PM - 11:15 PM CST


KEYNOTE-177研究:帕博利珠单抗vs 化疗治疗MSI-H晚期结直肠癌的Ⅲ期研究(Abs 6)

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

循环肿瘤DNA分析用于评估复发风险、辅助治疗获益和结直肠癌患者治疗后早期复发检测(Abs 11)

Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.

NRG-GI002研究:局部进展期直肠癌全程新辅助治疗(TNT)——帕博利珠单抗试验组队列(Abs 8)

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally-advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

GARNET研究:PD-1单抗Dostarlimab用于dMMR实体瘤患者的安全性与疗效(Abs 9)

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

肝胆癌、神经内分泌肿瘤/类癌、胰腺癌和小肠癌

Sunday, January 17,11:00 PM - 12:15 AM CST

全球Ⅲ期随机双盲ClarIDHy研究:IDH1突变的经治胆管癌患者中,Ivosidenib vs安慰剂的最终结果(Abs 266)

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

Ⅱ期BGJ398研究最终结果:Infigratinib用于既往接受过治疗的具有FGFR2基因融合或重排的晚期胆管癌患者(Abs 265)

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

Alliance A021501研究:术前mFOLFIRINOX或mFOLFIRINOX联合低分割放疗治疗临界可切除胰腺癌(Abs 377)

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

AXINET研究-GETNE-1107:奥曲肽联合阿昔替尼治疗晚期G1-G2非胰腺来源NETs患者的Ⅱ/Ⅲ期随机双盲研究(Abs 360)

A phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).

责任编辑:肿瘤资讯-Jelly
排版编辑:肿瘤资讯-Jelly

更多2021 ASCO-GI资讯,扫码关注专栏

专栏二维码2.jpg